Share

June 2015; 2 (3) ArticleOpen Access

Early CNS neurodegeneration in radiologically isolated syndrome

Christina J. Azevedo, Eve Overton, Sankalpa Khadka, Jessica Buckley, Shuang Liu, Mehul Sampat, Orhun Kantarci, Christine Lebrun Frenay, Aksel Siva, Darin T. Okuda, Daniel Pelletier
First published April 9, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000102
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1583

Share

Article Information

vol. 2 no. 3 e102
DOI: 
https://doi.org/10.1212/NXI.0000000000000102
PubMed: 
25884012
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 13, 2014
  • Accepted in final form March 5, 2015
  • First Published April 9, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Christina J. Azevedo, MD, MPH,
    2. Eve Overton, BS,
    3. Sankalpa Khadka, BS,
    4. Jessica Buckley, BS,
    5. Shuang Liu, PhD,
    6. Mehul Sampat, PhD,
    7. Orhun Kantarci, MD,
    8. Christine Lebrun Frenay, MD,
    9. Aksel Siva, MD,
    10. Darin T. Okuda, MD and
    11. Daniel Pelletier, MD
  1. Christina J. Azevedo, MD, MPH,
    2. Scientific Advisory Boards:

    1. I served on a medical advisory board for Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Race to Erase MS (Nancy Davis) Foundation Young Investigator Award

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Eve Overton, BS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Foundation of the Consortium of Multiple Sclerosis Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sankalpa Khadka, BS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jessica Buckley, BS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Shuang Liu, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mehul Sampat, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Bioclinica/Synarc, Senior Software Engineer, 2.5 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Orhun Kantarci, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Istanbul MS Days, Novartis Pharmaceuticals, speaker honoraria payment to Mayo Clinic

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Grant review for The National Multiple Sclerosis Society.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Already listed in the paper but reported again: Dr. Orhun Kantarci receives research support from the European Regional Development Fund (FNUSAICRC CZ.1.05/1.1.00/02.0123), the National Multiple Sclerosis Society, and has given a scientific presentation at a meeting supported by Teva Pharmaceuticals but has received no personal fees or personal compensation for this activity (all compensation for consulting activities paid directly to Mayo Clinic) nor has spoken about the specific medications involving this company. Dr.Kejal Kantarci serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])

    Research Support, Government Entities:

    1. Dr.Kejal Kantarci serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])

    Research Support, Academic Entities:

    1. Dr.Kejal Kantarci serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])

    Research Support, Foundations and Societies:

    1. 2006-2009 Multiple Sclerosis Society for support in multiple sclerosis research unrelated to this publication; 2008-2009 Mayo Foundation CR20 award for support in multiple sclerosis research unrelated to this publication; 2009-2011 Hilton Foundation support in multiple sclerosis research unrelated to this publication

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Christine Lebrun Frenay, MD,
    9. Scientific Advisory Boards:

    1. serving on a scientific advisory board from Biogen Idec, Merck Serono, Genzyme, Almirall, Allergan, Teva, Sanofi, Bayer Schering

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Funding for travel or speaker honoraria from Biogen Idec, Merck Serono, Genzyme, Almirall, Allergan, Teva, Sanofi, Bayer Schering

    Editorial Boards:

    1. Serving as editorial advisory board member for Revue Neurologique (Paris) Elsevier

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Aksel Siva, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr. Siva received travel and registration coverage for attending several national or international congresses or symposia, from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Novartis and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr Siva reports receiving honoraria or consultation fees from the commercial entities of Biogen Idec, Novartis and Teva within the last two years.

    Speakers' Bureaus:

    1. Giving educational presentations at programmes & symposia prepared by Excemed internationally - nonprofit entity

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Siva reports receiving research grants to his department from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants numbers : 109S070 and 112S052 - noncommercial entity. / unrelated to the study submitted

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Darin T. Okuda, MD and
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1. Acorda Therapeutics, travel and speaker fees 2. Genzyme, travel and speaker fees 3. Multiple Sclerosis Association of America, speaker fees 4. MS Cure Fund, speaker fees 3. TEVA Neuroscience, travel and speaker fees

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Genzyme 2. TEVA Neuroscience

    Speakers' Bureaus:

    1. 1. Acorda Therapeutics 2. Genzyme 3. TEVA Neuroscience

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Okuda received research support from Biogen IDEC.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Daniel Pelletier, MD
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. CNS Imaging Consultant, LLC

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have received research grant support from Biogen-Idec adn Hoffmann-LaRoche over the past two years.

    Research Support, Government Entities:

    1. I receive research grant support from NIH/NINDS R01-NS062885 (PI).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (C.J.A., E.O., S.K., J.B., S.L., M.S., D.P.) and Department of Diagnostic Radiology (D.P.), Yale University, New Haven, CT; Department of Neurology (O.K.), Mayo Clinic College of Medicine, Rochester, MN; Service de Neurologie (C.L.F.), Hospital Pasteur, Nice, France; Department of Neurology (A.S.), Cerrahpasa School of Medicine, University of Istanbul, Turkey; and Department of Neurology (D.T.O.), University of Texas Southwestern Medical Center, Dallas, TX.
  1. Correspondence to Dr. Azevedo: christina.azevedo{at}yale.edu

Article usage

Article usage: April 2015 to October 2023

AbstractFullPdfSource
Apr 20151921418Highwire
Apr 201503524pmc
May 20151121413Highwire
May 201506145pmc
Jun 20152763158Highwire
Jun 201504119pmc
Jul 2015711812Highwire
Jul 201503422pmc
Aug 20156117610Highwire
Aug 201502319pmc
Sep 20154238Highwire
Sep 201504327pmc
Oct 201539715Highwire
Oct 201503322pmc
Nov 201536710Highwire
Nov 201504120pmc
Dec 20152884Highwire
Dec 201503112pmc
Jan 201629115Highwire
Jan 201602221pmc
Feb 20163256Highwire
Feb 201603824pmc
Mar 20164089Highwire
Mar 201602410pmc
Apr 20163886Highwire
Apr 201602213pmc
May 20162084Highwire
May 201603323pmc
Jun 20162226Highwire
Jun 201601512pmc
Jul 20162822Highwire
Jul 201602121pmc
Aug 20162246Highwire
Aug 20160124pmc
Sep 20162052Highwire
Sep 2016021pmc
Oct 20162633Highwire
Oct 201602216pmc
Nov 20161625Highwire
Nov 20160209pmc
Dec 20162310Highwire
Dec 20160104pmc
Jan 20172522Highwire
Jan 2017093pmc
Feb 20171510Highwire
Feb 201701710pmc
Mar 20172933Highwire
Mar 20170137pmc
Apr 20172624Highwire
Apr 201751213pmc
May 20172112Highwire
May 201721313pmc
Jun 20171010Highwire
Jun 201781011pmc
Jul 20171601Highwire
Jul 2017112018pmc
Aug 20171614Highwire
Aug 2017267pmc
Sep 20172613Highwire
Sep 201771521pmc
Oct 20171430Highwire
Oct 2017366pmc
Nov 20172013Highwire
Nov 201791413pmc
Dec 20173125Highwire
Jan 20183131Highwire
Feb 20180594Highwire
Mar 20182313Highwire
Apr 20183155Highwire
Apr 201871314pmc
May 20180254Highwire
Jun 20188313Highwire
Jun 2018345pmc
Jul 2018122711Highwire
Aug 201811196Highwire
Aug 201851817pmc
Sep 20182244Highwire
Oct 20188417Highwire
Nov 20187333Highwire
Dec 20187568Highwire
Jan 20197227Highwire
Feb 20197267Highwire
Mar 2019113623Highwire
Apr 201917148Highwire
May 201913286Highwire
Jun 201986411Highwire
Jul 2019152410Highwire
Aug 2019167014Highwire
Sep 201913429Highwire
Oct 201916308Highwire
Nov 2019143111Highwire
Dec 201962114Highwire
Jan 2020182412Highwire
Feb 202092213Highwire
Mar 202051811Highwire
Apr 202012266Highwire
May 202093316Highwire
Jun 202052711Highwire
Jul 20206266Highwire
Aug 20204279Highwire
Sep 2020104614Highwire
Oct 2020174514Highwire
Nov 202052910Highwire
Dec 2020133510Highwire
Jan 202182314Highwire
Feb 20219167Highwire
Mar 2021194829Highwire
Apr 2021142214Highwire
May 202113347Highwire
Jun 202173511Highwire
Jul 202182419Highwire
Aug 2021122718Highwire
Sep 202191911Highwire
Oct 202184527Highwire
Nov 202152226Highwire
Dec 202192916Highwire
Jan 202252815Highwire
Feb 202251511Highwire
Mar 2022102713Highwire
Apr 202210359Highwire
May 2022101717Highwire
Jun 202242612Highwire
Jul 20228245Highwire
Aug 2022151867Highwire
Sep 2022167316Highwire
Oct 2022144613Highwire
Nov 2022149327Highwire
Dec 202285111Highwire
Jan 2023118228Highwire
Feb 202394623Highwire
Mar 202385525Highwire
Apr 202381721Highwire
May 202372010Highwire
Jun 20235156Highwire
Jul 202361613Highwire
Aug 202341710Highwire
Sep 202362411Highwire
Oct 20236237Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles